RP-182 is a synthetic immunomodulatory peptide that exerts antitumor effects by targeting the mannose receptor CD206 on the surface of tumor-associated macrophages (TAM) with a binding affinity (Kd) of 8 μM. It induces a conformational change in the CD206 receptor, which activates NF-κB signaling and phagocytosis in TAM with high CD206 expression. RP-182 serves a dual function by activating the canonical NF-κB signaling pathway, leading to TNFα secretion and autocrine activation of TNF receptor 1 (TNFR1), which subsequently results in caspase 8 activation and apoptosis. This compound is studied in the contexts of pancreatic cancer and melanoma.